News Bavarian and BMS press on with Opdivo and cancer vaccine com... BMS hopes combinations will maintain Opdivo lead after setback
Views & Analysis Promise for combination approach to cancer As immuno-oncology increasingly involves more than one agent for best efficacy, market positioning must take a pan-tumour approach.
News Adcetris falls victim to NICE’s Cancer Drugs Fund clear-out More CDF legacy products likely to face same fate
News AZ urges others to join genomic research consortium Data gathered from Patient Derived Xenografts will aid drug and biomarker discovery.
News BMS' Opdivo stumbles in lung cancer, but could still maintai... Analysts expect Opdivo to recover via combination trials
Views & Analysis Tunnah’s musings: Lessons for pharma from digital ASCO 2016 Pharma needs to remedy its approach to digital conference engagement.
News Angelini Pharma's R&D chief heads for the exit Dr Rafal Kaminski's near five-year tenure as chief scientific officer of Italy's Angelini Pharma will come to an end in the next couple of weeks.
Sales & Marketing Sponsored Securing your ROI: Turning post-acquisition integration into... Join Forinnovia and Little Cube Consulting for a webinar on securing post-acquisition ROI.